All In MedTech

FDA Clearance Tracker · P160052-S001

PartoSure Test

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 11, 2019

Approved

Time to decision

518 days

Received May 11, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160052-S001
Device name
PartoSure Test
Applicant
Qiagen, Inc.
Applicant location
Germantown, MD
Received
May 11, 2018
Decided
Oct 11, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160052

Device type

Device class
Class III

Every decision under product code QBB

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) protocol

Source documents

Other decisions for Qiagen, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.